tbuckley/cabot-search huggingface dataset:
ROS-Responsive Mitochondria-Targeting Blended Nanoparticles: Chemo- and Photodynamic Synergistic Therapy for Lung Cancer with On-Demand Drug Release upon Irradiation with a Single Light Source
Authors: Caixia Yue, Yuming Yang, Chunlei Zhang, Gabriel Alfranca, Shangli Cheng, Lijun Ma, Yanlei Liu, Xiao Zhi, Jian Ni, Weihua Jiang, Jie Song, Jesús M. de la Fuente, Daxiang Cui
Journal: Theranostics (2016)

Mitochondria in cancer cells maintain a more negative membrane potential than normal cells.Mitochondria are the primary source of cellular reactive oxygen species (ROS), which are necessary for photodynamic therapy.Thus, the strategy of targeting mitochondria can maximize the photodynamic therapeutic efficiency for cancer.Here we report, for the first time, synthesis of a new mitochondria-targeting drug delivery system, ZnPc/CPT-TPPNPs.To synthesize this novel compound, polyethylene glycol was functionalized with thioketal linker-modified camptothecin (TL-CPT) and triphenylphosphonium to form the block copolymer, TL-CPT-PEG1K-TPP.The ZnPc/CPT-TPPNPs was constructed for delivery of the photosensitizer Zinc phthalocyanine (ZnPc) by blending the block copolymer TL-CPT-PEG1K-TPP with 1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)] (DSPE-PEG).Triphenylphosphine can accumulate selectively several hundred-fold within mitochondria.The thioketal linker is ROS-responsive and CPT can be released upon ROS cleavage.We also show that the ZnPc loaded in ZnPc/CPT-TPPNPs absorbed the 633 nm laser to produce ROS, which could be utilized both in photodynamic therapy and to cleave the thioketal linker thereby releasing camptothecin for chemotherapy.Thus, the mitochondria-targeting nanoparticles could elevate photodynamic therapeutic efficacy.Our results showed that surface modification of the nanoparticles with triphenylphosphine cations facilitated efficient subcellular delivery of the photosensitizer to mitochondria.The nanoparticles had a good ROS-responsive effect to release CPT, which could transfer to the nucleus and interfere with DNA replication as a topoisomeraseⅠinhibitor.Thus, the blended nanoparticles provide a new promising approach as a mitochondria-targeting ROS-activated chemo-and photodynamic therapy with a single light source for lung cancer.
B cells differentiate in human thymus and express AIRE
Authors: Vincent Gies, Aurélien Guffroy, François Danion, Philippe Billaud, Céline Keime, Jean-Daniel Fauny, Sandrine Susini, Anne Soley, Thierry Martin, Jean-Louis Pasquali, Frédéric Gros, Isabelle André-Schmutz, Pauline Soulas-Sprauel, Anne-Sophie Korganow
Journal: Journal of Allergy and Clinical Immunology (2016)
Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.
Authors: Carlos A. Ramos, Rima M. Saliba, Ola Khorshid, Leandro de Padua, Sergio Giralt, Borje S. Andersson, Naoto T. Ueno, Elizabeth J. Shpall, Issa F. Khouri, Chitra Hosing, Amin Alousi, Yago Nieto, Suhail R. Qureshi, Richard E. Champlin, Marcos de Lima
Journal: Blood (2007)
P289 Drug product performance through inhaler life using a lama/laba combination in a dry powder inhaler
Authors: J Plugge, U Basaldella, B Fyrnys, T Pieper
Journal: Thorax (2016)

<h3>Introduction</h3> Studies to test the delivered dose uniformity (DDU) and fine particle dose (FPD) delivery over inhaler life were performed with aclidinium bromide 400 μg/formoterol fumarate dihydrate 12 μg inhalation powder in the Genuair™* inhaler. <h3>Methods</h3> Developmental batches representative for commercial production were used. Samples were tested after release, and after 24 months of protected (pouched samples) stability storage at climatic zone II conditions. In-use tests were performed with unprotected samples over 2 months at climatic zone II conditions, both shortly after batch production (‘fresh samples’) and after protected pre-storage at climatic zone II conditions for 35 months. In addition, mass balance and mouthpiece deposition were assessed. <h3>Results</h3> The studies show consistent performance through inhaler life from release up to 24 months of protected storage; all data were well inside the acceptance criteria applied during development. An example for the LABA active ingredient, formoterol fumarate dihydrate, is given in Figure 1. Furthermore, during in-use studies over 2 months, no impact of climatic zone II conditions on DDU and FPD could be detected, both for fresh samples and samples pre-stored for up to 35 months. No significant first delivered dose effect was seen; the slightly lower first doses are explained by mouthpiece deposition, as shown in Figure 1 for the LABA and the LAMA (aclidinium bromide) active ingredient. The mouthpiece deposition per actuation/dose ranged from 6.5% for actuation 1 to 1.3% for actuation 60 for the LABA active ingredient, and from 4.9% for actuation 1 to 1.2% for actuation 60 for the LAMA active ingredient. <h3>Conclusions</h3> The drug product delivers consistent doses and fine particle doses through inhaler life. Mouthpiece deposition is determined to be low, showing no effect on the drug product performance. *Registered trademark of AstraZeneca group of companies; for use within the USA as Pressair® and Genuair™ within all other licensed territories.
SAT0629-HPR Rapid Access Triage Clinic: A Nursing Service That Shortens Rheumatology Clinic Waiting Time and Facilitates Early Treatment
Authors: S.K.G. Kwok, L.M.M. Tang, H.Y.J. Chung, K.Y.C. Yuen, T.K.C. Ho, C.S. Lau
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The waiting time for newly referred patients to the rheumatology clinic is approximately 24 months. The Rheumatology Nurse Rapid Access Triage Clinic aims to shorten the waiting time of patients suspected to have rheumatoid arthritis (RA). It is hoped that patients with active RA can be fast-tracked to commence earlier treatment for better disease control. <h3>Objectives</h3> To validate if Rheumatology Nurses (RhN) can screen out patients with active RA for earlier treatment and to evaluate the level of agreement in RA diagnosis between RhN and rheumatologists. <h3>Methods</h3> Newly referred patients suspected to have RA were assessed by RhN from March 2012 to September 2015. Based on a protocol modelled upon the 2010 European League Against Rheumatism (EULAR)/American College of Rheumatologists (ACR) criteria for the classification of RA, RhN performed history taking, physical examination of joints, and ordered relevant blood and X-ray investigations. RhN then reviewed all results to discriminate between RA and non-RA. Paired t-tests and logistic regression were used to compare variables between RA and non-RA patients diagnosed by RhN. Correlation coefficient (CC) was used to compare the level of agreement between RhN9s and rheumatologists9 assessment. <h3>Results</h3> RhN assessed 102 patients (mean age =53.46 ± 12.59 years, 84.3% women). The group diagnosed to have RA by RhN had shortened waiting time for the rheumatology clinic when compared to the non-RA group. (11.5 vs 3.6 months; p&lt;0.001) Agreement between RhN diagnosed RA and rheumatologist diagnosed RA was excellent (CC 90%; P&lt;0.001). Comparing with the non-RA group, RhN diagnosed RA group also had greater chance of receiving disease modifying anti-rheumatic drugs (DMARDs) early (OR 43.08, p&lt;0.001). The mean duration between onset of joint symptom and DMARDs commencement was 8.26 ± 11.52 months ranging from 3 to 52 months. <h3>Conclusions</h3> The Rheumatology Nurse Rapid Access Triage Clinic provides accurate diagnosis and shortens RA patient9s waiting time. It also helps to screen out active patients to receive earlier treatment. <h3>References</h3> Gormley GJ, Steele WK, Gilliland A, Leggett P, Wright GD, Bell AL, Matthew C, Meenagh G, Wylie E, Mulligan R, Stevenson M, Reilly DO and Taggart AJ (2003) Can diagnostic triage by general practitioners or rheumatology nurses improve the positive predictive value of referrals to early arthritis clinics? Rheumatology 42:763–768. <h3>Disclosure of Interest</h3> None declared
Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study
Authors: Fatmah Othman, Colin J Crooks, Timothy R Card
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To examine the risk of community acquired pneumonia before and after prescription of proton pump inhibitor (PPI) and assess whether unmeasured confounding explains this association. <b>Design</b>&nbsp;Cohort study and self controlled case series. <b>Setting</b>&nbsp;Clinical Practice Research Datalink (1990 to 2013) in UK. <b>Participants</b>&nbsp;Adult patients with a new prescription for a PPI individually matched with controls. <b>Main outcome measures</b>&nbsp;Association of community acquired pneumonia with PPI prescription estimated by three methods: a multivariable Cox model comparing risk in PPI exposed patients with controls, corrected for potential confounders; a self controlled case series; and a prior event rate ratio (PERR) analysis over the 12 month periods before and after the first PPI prescription. <b>Results</b>&nbsp;160 000 new PPI users were examined. The adjusted Cox regression showed a risk of community acquired pneumonia 1.67 (95% confidence interval 1.55 to 1.79) times higher for patients exposed to PPI than for controls. In the self controlled case series, among 48 451 PPI exposed patients with a record of community acquired pneumonia, the incidence rate ratio was 1.19 (95% confidence interval 1.14 to 1.25) in the 30 days after PPI prescription but was higher in the 30 days before a PPI prescription (1.92, 1.84 to 2.00). The Cox regressions for prior event rate ratio similarly showed a greater increase in community acquired pneumonia in the year before than the year after PPI prescription, such that the analysis showed a reduced relative risk of pneumonia associated with PPI use (prior event rate ratio 0.91, 95% confidence interval 0.83 to 0.99). <b>Conclusion</b>&nbsp;The association between the use of PPIs and risk of community acquired pneumonia is likely to be due entirely to confounding factors.
The Follicular Lymphoma International Prognostic Index (FLIPI) Can Be a Useful Prognostic Indicator for Patients with Follicular Lymphoma Treated with Combination of Rituximab and Epratuzumab.
Authors: Sandra J. Strauss, Franck Morschhauser, Martin Gramatzki, Philippe Solal-Celigny, Pier L. Zinzani, Andreas Engert, Bertrand Coiffier, Dieter Hoelzer, Nick Teoh, William A. Wegener, David M. Goldenberg, Ivan D. Horak, Thomas A. Lister
Journal: Blood (2005)
THU0494 Skin Events with Febuxostat in Gout Patients with Previous Skin Reactions To Allopurinol. A Retrospective Review:
Authors: N. Quilis, M. Andrés, P. Vela, E. Pascual
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Allopurinol is the most used urate-lowering agent for patients with gout. However, 10% of patients show intolerance to this drug, often at skin, which can be severe. Febuxostat is a novel non-purine selective xanthine oxidase inhibitor that has been proposed for allopurinol-intolerant patients due to its different structure. However, data regarding safety in those with previous skin reactions to allopurinol is still limited (1,2). <h3>Objectives</h3> To assess the cutaneous safety of febuxostat when used in patients with previous skin reactions to allopurinol. <h3>Methods</h3> Retrospective review of patients with crystal-proven gout treated with febuxostat in our Unit until December 2015. Those with previous skin reaction to allopurinol were selected. We registered epidemiological (age, gender), clinical (skin events) and laboratory variables (serum uric acid, glomerular filtration rate). The primary study variable was the rate of patients also presenting skin reactions with febuxostat. A descriptive analysis with estimation of the 95% confidence interval (95%CI) was performed. <h3>Results</h3> Out 102 gout patients treated with febuxostat in our Unit, we identified 24 patients with prior allopurinol-related skin events. The median age was 68.5 years (p25-p75 53.7–71.0), being 18 males (75%). Most used starting dose of febuxostat was 80mg/d (n=16), others were 5mg/d (n=1), 40mg/d (n=4) or 120mg/d (n=3). Median glomerular filtration rate at that time was 77.2 mL/min (62.7–68.6). We have identified five patients (20.8%; 95%CI 3–38%) who also developed skin reactions with febuxostat (see table): in four cases a nonspecific rash, but one suffered from a Stevens-Johnson syndrome. None of these patients presented skin reactions to benzbromarone. <h3>Conclusions</h3> In our series, one out five patients with previous skin reaction to allopurinol also developed after febuxostat. Larger studies are needed to confirm these results, but this finding strengths caution when using febuxostat in this subgroup of patients. <h3>References</h3> J Rheumatol 2011;38;1957. Joint Bone Spine 2015 Dec 18. <h3>Disclosure of Interest</h3> None declared
Molecular Basis of Congenital Dyserythropoietic Anemia Type I in French Patients.
Authors: Hannah Tamary, Orly Dgany, Alexis Proust, Tanya Krasnov, Nili Avidan, Gil Tchernia, David Geneviève, Valérie Comier-Darre, Martine Le Merrer, Brigitte Bader-Meunier, Corinne Ferrero-Vacher, Isaac Yaniv, Jean Delaunay
Journal: Blood (2004)
Multiple Brain Hemorrhages on Presentation in a Patient with Accelerated Phase Chronic Myeloid Leukemia and Subsequent CNS Blast Crisis Despite Systemic Complete Molecular Response: Possible Role of CNS Bleed in Leukemia Proliferation
Authors: Aleem Aamer, Fatmah Al Wusibai, Khalid AlSaleh, Fatma Alqahtani, Zafar Iqbal, Naeem A. Chaudhri, Abdul Kareem M Al-Momen
Journal: Blood (2015)
Prognostic Impact of Genetic Subgroups and Development of Gene Classifiers for Response, PFS and OS In Multiple Myeloma Patients Treated with Bortezomib or Conventional Agents In HOVON65/GMMG-HD4 Trial
Authors: Annemiek Broyl, Rowan Kuiper, Martin H. van Vliet, Erik H. van Beers, Yvonne de Knegt, Bronno van der Holt, Laila el Jarari, Berna Beverloo, H. Lokhorst, Sonja Zweegman, George Mulligan, Hartmut Goldschmidt, Mark van Duin, Pieter Sonneveld
Journal: Blood (2010)
Thrombophilia as a Risk Factor for Central Retinal Vein Thrombosis.
Authors: Fotios I Girtovitis, Elisabet Tsakiroglou, Michael D. Diamantidis, Zoi Saouli, Zisis Kontoninas, Virginia Voulgaridou, Ilias Merakis, Georgia Kaiafa, Athanasios Papadopoulos Sr.
Journal: Blood (2009)
Low Levels of 25-Hydroxyvitamin D Prior to Allogeneic Transplantation Correlate with the Development of Chronic Graft-Versus-Host Disease,
Authors: Brett Glotzbecker, Vincent T Ho, Julie Aldridge, Haesook T Kim, Gary Horowitz, Jerome Ritz, Robert J. Soiffer, David Avigan, Jacalyn Rosenblatt
Journal: Blood (2011)
Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia (pB-ALL) Detected by Comparative Genomic Hybridization.
Authors: Amer Zeidan, Dan Gaile, Jeffrey M. Conroy, Devin E. McQuaid, Eunice S. Wang, George Deeb, Paul K. Wallace, Sheila N.J. Sait, Norma J. Nowak, Meir Wetzler
Journal: Blood (2007)
Overall Survival in Cancer Drug Trials as a New Surrogate End Point for Overall Survival in the Real World
Authors: Sham Mailankody, Vinay Prasad
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
원저 : 만성 B형 간질환에서 라미부딘 초치료 후의 재발 양상과 재치료 효과
Authors: 박종호, Neunghwa Park, shin jung woo, 방성조, 김대현, 주광로, Do Ha Kim
Journal: Clinical and Molecular Hepatology (2003)

목적 : 만성 B형 간염 환자에 라미부딘은 효과적이지만 서양의 보고와 달리 국내에서는 치료 종료 후 재발률이 높은 것으로 알려져 있다. 그러나 라미부딘 치료 종료 후의 재발 양상이나 재발군에서 라미부딘의 재투여에 대한 치료 효과는 알려져 있지 않다. 본 연구에서는 치료 종료 후 재발 양상과 재발군에서 라미부딘 재치료 효과를 알아보고자 하였다. 대상과 방법: 만성 B형 간질환으로 진단 받고 라미부딘을 치료받은 환자 중 치료에 반응한 후 투약을 중지한 121명 중에서 재발한 42명(만성간염 36예, 대상성 간경변 6예)을 대상으로 하였다. 라미부딘은 1일 100mg씩 6개월(평균 16개월, 범위: 6-35개월) 이상 투여하였다. 평균 연령은 39.7에였고 남녀 비는 35:7이었다. 재치료 전 혈청 ALT 평균치는 437 IU/L, AST 평균치는 227 IU/L, HBV DNA 평균치는 519pg/mL였다. 치료반응군에서는 치료 반응이 있은 뒤 추가로 라미부딘을 투여하여 적어도 2개월 이상 반응이 유지된 후 투약을 중지하고 재발 유무를 추적 관찰하였다. 결과: HBeAg이 혈청전환된 192예 중 121예(63%)에서 투여를 중단하였으며 평균 추적 기간은 8.9개월(범위: 1-40개월)이었다. 66명(54.5%)에서 재발하였으며 평균 재발 시기는 5.7개월(범위: 1-33개월)이었다. 50예(75.8%)에서는 HBeAg 양성 만성 간질환으로, 16예(24.2%)는 HBeAg 음성 만성 간질환으로 재발하였다. 누적 재발률은 1개월 후 6%, 3개월 후 27%, 6개월 후 47%, 12개월 후 60%, 18개월 후 64%, 24개월 후 66%이었다. 재발과 관련된 예측 인자로는 연령, 치료 전 정량적 HBeAg치, HBV DNA치가 의미 있는 인자였으며 30세 이하의 25명 중 5명만이 재발하였다. 재발한 66명 중에서 혈청 ALT치가 지속적으로 상승된 42예(64%)에서 라미부딘을 재투여 하였다. 31예(73.8%)에서 반응이 있었으며 누적 치료 반응률은 6개월 62%, 9개월 69%, 12개월 72%였다. Breakthrough는 6예(14.3%)에서 일어났으며 전부 HBeAg 양성 만성 간질환 환자였다. 적어도 2개월 이상 치료반응이 유지된 21예에서 투여를 중지하였으며 이중 11예(52.4%)에서 재발하였다. 재치료한 HBeAg 양성군과 음성군 간에 치료반응률, breakthrough률, 재발률 등도 유의한 차이는 없었다. 라미부딘 투여기간(p=0.003)이 유의하였으며 breakthrough와 관련된 인자는 없었다. 결론: 라미부딘 초치료 후 재발률은 높았으며 재바 형태는 HBeAg 양성뿐만 아니라 HBeAg 음성 만성 B형 간질환의 형태로도 나타났다. 라미부딘 재치료는 초치료보다는 높은 치료 반응률을 보였으나 breakthrough률과 재발률은 초치료와 비슷하였다.
PWE-161 Preventing Post-ERCP Pancreatitis (PEP): The Role of Prophylactic Pancreatic Duct Stenting In The Rectal NSAID era
Authors: N Bekkali, T Thomas, S Murray, D Joshi, G Johnson, M Chapman, S Pereira, G Webster
Journal: Gut (2016)

<h3>Introduction</h3> Post ERCP pancreatitis (PEP) is an important complication. Rectal NSAIDs at ERCP is the standard of care to reduce the risk. Pancreatic duct (PD) stenting also reduces the risk of PEP in high risk patients, but placement can be technically challenging. Failed PD stenting carries reported PEP rates of at least 35%. We aimed to assess whether prophylactic pancreatic stenting is still justified in the current rectal NSAID era. <h3>Methods</h3> Between January 2013 and June 2015, we retrospectively evaluated the use of PD stents in a UK tertiary referral centre. Rectal NSAIDs were used universally for all cases post-ERCP, except in those contraindicated to NSAIDs. Prophylactic PD stenting (unflanged 5Fr 5–7 cm single pigtail stents, Cook Medical) was attempted in predicted high risk PEP cases. Indications for therapeutic PD stents included patients with chronic pancreatitis. Data was collected from our prospective database, completed following each ERCP. Follow-up information was reviewed through electronic records and telephone enquiry. <h3>Results</h3> 1633 ERCPs were performed during the study period. Pancreatic stenting was attempted in 324 cases (20%); successful placement was achieved in 307 cases (95%). Prophylactic PD stenting failed in 12 cases, one case developed PEP (1/12 = 8%). This patient had sphincter of Oddi dysfunction (SOD) and a contraindication to NSAIDs. 65% (201/307), of successfully placed pancreatic stents were inserted prophylactically, in whom 9% (18/201) developed PEP. PEP occurred in 1.4% (18/1309) of cases who did not undergo attempted PD stenting. The relative risk of PEP was 8.4 (p = 0.04) in the stented group. <h3>Conclusion</h3> PEP rates in failed PD stenting were low (8%) compared to past studies, and comparable to PEP rates in successful prophylactic PD stenting. This suggests a protective role of rectal NSAIDs, as previously shown by Choksi et al.<sup>1</sup> The higher rate of PEP in the PD stenting/attempted stenting group, compared to the unstented group, likely reflects the higher perceived risk of PEP in the PD stenting group. The low rate of recorded PEP in the unstented group may, in part, be due to under-reporting. Our data suggests that increased rates of PEP continue to be seen in perceived high risk cases, even in a universal NSAID use setting. The overall risk appears lower than in the pre-NSAID era, and in our series a lack of difference in the PEP rate between successful and failed PD stenting suggests there is less need for prophylactic PD stenting in the NSAID era. <h3>Reference</h3> 1 Choksi, <i>et al</i>. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement <i>Gastrointest Endosc</i> 2015;<b>81</b>(1):150–155. <h3>Disclosure of Interest</h3> None Declared
Comprehensive analysis of a myeloperoxidase-negative acute promyelocytic leukemia
Authors: Maël Heiblig, Etienne Paubelle, Adriana Plesa, Marie-Oldine Geay, Delphine Manzoni, Sophie Gazzo, Isabelle Tigaud, Evelyne Callet-Bauchu, Sarah Huet, Gilles Salles, Xavier Thomas, Sandrine Hayette, Pierre Sujobert
Journal: Blood (2016)
Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.
Authors: Uwe Klueppelberg, Iuliana Shapira, Eric Smith, Marc Braunstein, David Kahn, Yury Pertsovsky, Olcay Batuman
Journal: Blood (2005)